EBMT 2024 | The current landscape for the treatment of R/R AML in the post-transplant setting
Simona Pagliuca, MD, PhD, Nancy University Hospital, Nancy, France, discusses current research into treatment options for patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) post-transplant. Strategies that manipulate donor lymphocyte infusion (DLI) are currently used to prevent relapse, although evidence is mainly retrospective. The FLT3 inhibitors gilteritinib and sorafenib are the only agents approved in this setting, but many more are under investigation, including azacitidine, IDH inhibitors, and eprenetapopt. Dr Pagliuca mentions that clinical trials investigating CAR-T therapies have started to include patients who have relapsed post-transplant. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
